Volastra Therapeutics, Inc.

This study tests a new oral drug called sovilnesib in people with advanced high-grade serous ovarian cancer that has stopped responding to platinum chemotherapy. The main goal is to find the safest and most effective dose by monitoring side effects and tumor response. About 120 p…